- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Patricia Coyle, MD, Discusses Treatment of Multiple Sclerosis
Patricia Coyle, MD, director, MS Comprehensive Care Center, Stony Brook Neurosciences Institute, professor and vice chair of clinical affairs, Department of Neurology, SUNY at Stony Brook, says that prognostically, the earlier you treat multiple sclerosis the better.
Patricia Coyle, MD, director, MS Comprehensive Care Center, Stony Brook Neurosciences Institute, professor and vice chair of clinical affairs, Department of Neurology, SUNY at Stony Brook, says that prognostically, the earlier you treat multiple sclerosis the better.
Dr Coyle says “very interesting long-term data” demonstrates that younger MS patients and lower Expanded Disability Status Scale patients who are treated, do better later and have less disability. “I think that’s really reinforcing the concept of a window of opportunity,” she says.
Balancing Cost and Quality in Oncology: A Value-Based Care Perspective
January 30th 2025Travis Brewer, vice president of payer and public health strategy/relations at Texas Oncology, shared that value-based oncology care can achieve both cost efficiency and high-quality outcomes through integrated multidisciplinary teams, flexible payment models, and targeted treatment approaches.
Read More
Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees
January 23rd 2025On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.
Listen
How FcRn Blockade Targets Myasthenia Gravis Autoantibodies
January 29th 2025In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.
Read More
